Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Shares Issued (2016 - 2025)

Celldex Therapeutics has reported Shares Issued over the past 16 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Shares Issued at $1.3 million for Q4 2025, up 100.32% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (down 73.9% YoY), and the annual figure for FY2025 was $2.4 million, down 73.9%.
  • Shares Issued for Q4 2025 was $1.3 million at Celldex Therapeutics, up from $774000.0 in the prior quarter.
  • Over the last five years, Shares Issued for CLDX hit a ceiling of $432.3 million in Q1 2024 and a floor of -$424.8 million in Q2 2024.
  • Median Shares Issued over the past 5 years was $365000.0 (2021), compared with a mean of $11.7 million.
  • Peak annual rise in Shares Issued hit 165180.93% in 2024, while the deepest fall reached 319478.95% in 2024.
  • Celldex Therapeutics' Shares Issued stood at $426000.0 in 2021, then skyrocketed by 227.46% to $1.4 million in 2022, then skyrocketed by 15322.08% to $215.1 million in 2023, then crashed by 296.69% to -$423.1 million in 2024, then soared by 100.32% to $1.3 million in 2025.
  • The last three reported values for Shares Issued were $1.3 million (Q4 2025), $774000.0 (Q3 2025), and $63000.0 (Q2 2025) per Business Quant data.